Medical Treatment of Crohn's Disease

Aaron Brzezinski

doi:10.1055/s-2001-15855

Clinics in Colon and Rectal Surgery, Table of Contents

Clin Colon Rectal Surg 2001; 14(2): 167-174
DOI: 10.1055/s-2001-15855

Medical Treatment of Crohn's Disease

Aaron Brzezinski

Department of Gastroenterology, The Cleveland Clinic, Cleveland, OH

Abstract

ABSTRACT

Medical treatment of Crohn's disease has progressed from empiric pharmaceuticals to biological agents. These medications help induce and maintain remission, prevent postoperative recurrence, improve quality of life, and suppress intestinal inflammation. A multidisciplinary team composed of surgeons, physicians, enterostomal therapists, and dietitians optimizes therapy and helps to minimize complications.

KEYWORD

Crohn's disease - medical treatment - corticosteroids

Full Text

References

REFERENCES

1 Azad Khan K A, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet . 1977; 2 892-895
2 Thomson A BR, Wright J P, Vatn M. Mesalazine (Mesasal/Claversal) 1.5 g b.d. versus placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther . 1995; 9 673-683
3 McLeod R S, Wolff B G, Steinhart A H. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology . 1995; 109 404-413
4 Camma C, Giunta M, Rosselli M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology . 1997; 113 1465-1473
5 Lochs H, Mayer M, Fleig W E. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI. Gastroenterology . 2000; 118 264-273
6 Summers R W, Swit D M, Session J T. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology . 1979; 77 847-869
7 Malchow H, Ewe K, Brandes J W, Goebell H, Ehms H. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology . 1984; 86 249-266
8 Singleton J W, Hanauer S B, Gitnick G L, Peppercorn M A, Robinson M G. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology . 1993; 104 1293-1301
9 Hanauer S B, Krawitt E L, Robinson M, Rick G G, Safdi M A. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Am J Gastroenterol . 1993; 88 1343-1351
10 Ursing B, Alm T, Barany F. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology . 1982; 83 550-562
11 Prantera C, Zannoni F, Scribano M L. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol . 1996; 91 328-332
12 Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology . 1995; 108 1617-1621
13 Colombel J F, Lemann M, Cassagnon M. GETAID: a controlled trial comparing ciprofloxacin and mesalazine for the treatment of active Crohn's disease. Gastroenterology . 1997; 112 A951
14 Giu G PH, Thomas P RS, Tizard M LV, Sanderson J D, Hermon-Taylor J. Two-year outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother . 1997; 39 393-400
15 Summers R W, Switz D M, Sessions Jr T J. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology . 1979; 77 847-869
16 Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut . 1994; 35 360-362
17 Rutgeerts P, Lofberg R, Malchow H. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med . 1994; 331 842-845
18 Feagan B, Greenberg G R, Lofberg R. Budesonide controlled release ileal release prolongs remission in Crohn's disease: a pooled analysis. Gastroenterology . 1997; 112 A970
19 Hellers G, Cortot A, Jewell D. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology . 1999; 116 294-300
20 Schoon E J, Blok B M, Geerling B J. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology . 2000; 119 1203-1208
21 Hanauer S, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol . 1997; 92 559-566
22 Present D, Korelitz B I, Wisch N. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomized double blind study. N Engl J Med . 1980; 302 981-987
23 Markowitz J, Grancher K, Kohn N. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology . 2000; 119 895-902
24 Connell W R, Kamm M A, Dickson M, Balkwill A M, Ritchie J L, Lennard-Jones J E. Safety of low-dose purine analogues in inflammatory bowel disease. Gastroenterology . 1994; 107 1905-1906
25 Lewis J D, Sanford Schwartz J, Lichtenstein G R. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology . 2000; 118 1018-1024
26 Duchesne D, Latours S, Leclerc J M, Sallan S E, Theoret Y. Pharmacokinetics of oral and intravenous 6-mercaptopurine (6-MP) in childhood acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol . 1994; 13 A341
27 Otterness D, Szumlanski C, Lennard L. Human thiopurine methyl-transferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther . 1997; 62 60-73
28 Weinshilboum R M, Sladek S L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet . 1980; 32 651-662
29 Dubinsky M C, Lamothe S, Yang H Y. Optimizing and individualizing 6-MP therapy in IBD: the role of 6-MP metabolite levels and TPMT genotyping. Gastroenterology . 1990; 116 A702
30 Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut . 1996; 39 401-406
31 Cuffari C, Picco M, Hunt S. Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD. Gastroenterology . 1999; 116 A694
32 Dubinsky M C, Lamothe S, Yang H Y. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology . 2000; 118 705-713
33 Achkar J P, Stevens T, Brzezinski A. 6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy (abstract). Am J Gastroenterol . 2000; 96 2491
34 Feagan B G, Rochon J, Fedorak R N. Methotrexate for the treatment of Crohn's disease. N Engl J Med . 1995; 332 292-297
35 Feagan B G, Fedorak R N, Irvine E J. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med . 2000; 342 1627-1632
36 Van Dullemen M H, Van Deventer J H S, Hommes D W, Bijl H A, Jansen J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology . 1995; 109 129-135
37 Targan S R, Hanauer S B, Sander H H. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med . 1997; 337 1029-1035
38 Present D H, Rutgeerts P, Targan S. Infliximab treatment of fistulas in patients with Crohn's disease. N Engl J Med . 1999; 340 1398-1405
39 Rutgeerts P, D'Haens G, Targan S. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology . 1999; 117 761-769
40 Hanauer S B, Cohen R D, Becker R V. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther . 1998; 20 1009-1028
41 Mate J, Castanos R, Garcia-Samaniego J, Pajares J M. Does dietary fish oil maintain remission of Crohn's disease: a study case control. Gastroenterology . 1991; 100 A228
42 Beluzzi A, Brignola C, Campieri M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med . 1996; 334 1557-1560
43 Gonzalez-Huix F, de Leon R, Fernandez-Banares F. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut . 1993; 34 778-782
44 Sampaio E P, Kaplan G, Miranda A. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis . 1993; 168 408-414
45 Ehrenpreis E D, Kane S K, Cohen L B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology . 1999; 117 1271-1277
46 Vasiliauskas E A, Kam L Y, Abreu-Martin M T. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology . 1999; 117 1278-1287
47 Zeldis J B, Williams B A, Thomas S D. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther . 1999; 21 319-330